ViroVet wins pitching competition


ViroVet NV, a leading Belgian biopharmaceutical company active in the development of antiviral drugs and innovative vaccines for use in livestock, announced today that it has won the pitching competition organised by PwC.

The finalists of the pitching competition had just 3 minutes each to convince the jury and the audience about the innovative aspects and scalability of their business concept and/or technology.

Erwin Blomsma, co-founder and CEO of ViroVet “to pitch as biotech with a complicated and disruptive technology along start-ups active in augmented reality, blockchain technology or mobile apps is very special. To stand out in such a mix and being able to share our enthusiasm for livestock innovations with such a diverse audience feels great.”


As winner of the Pre-Slush pitching competition ViroVet got a voucher for what many people call the Tomorrowland of the start-up world: the impressive Slush event in Helsinki in December this year. In Helsinki more than 2600 start-ups, 1600 investors, 600 journalists and over 20000 attendees are expected. PwC has been partnering with Slush since 2010 and in 2015 PwC became Slush’s first global partner.


Along with Slush, PwC plays an active role in developing startup ecosystems around the world and supporting entrepreneurs as they work to get their ideas off the ground and build sustainable businesses.


About ViroVet
ViroVet is a biopharmaceutical company with a clear objective to develop innovative technologies to improve the health and value of livestock. The company is headquartered in Leuven (Heverlee), Belgium and has a pipeline of antiviral drugs and thermostable vaccines.


About Slush
More information about Slush:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?